UPDATES ON COVID-19 RESTRICTION OF MOVEMENT ORDERMARCH 17. 2020 @ 10.13PM
Malaysia will be under a nationwide movement control order from March 18 - 31 due to the Covid-19 outbreak, Prime Minister Tan Sri Muhyiddin Yassin announced today.
Enforced under the Prevention and Control of Infectious Diseases Act 1988 & The Police Act 1967, the restriction of movement order will impose the following: (a) No mass gatherings - general prohibition on mass movements and gatherings including religious, sports, social and cultural activities. (b) Closure of premises – including houses of worship, business premises, all government and private premises as well as non-essential businesses such as MBO, TGV and GSC cinemas are to close. Exceptions are for supermarkets, public markets, convenience stores and those involved in essential services such as water, electricity, energy, telecommunication, postal, transportation, irrigation, oil, gas, fuel, lubricants, broadcasting, finance, banking, health, pharmacy, fire, prison, port, airport, safety, defence, cleaning, retail and food supply will be open. (c) Closure for education sector: (i) kindergartens, government and private schools, boarding schools, pre-university institutions; and public and private higher education institutions (IPTs) and skills training institutes are to close. (d) Travel ban and requirements: (i) Malaysian citizens are prohibited from exiting out of Malaysia; (ii) Malaysian citizens returning from overseas travel must undergo a health check and be self-quarantined for 14 days; and (iii) all tourists and foreign visitors are prohibited from entering Malaysia. The Health Ministry earlier confirmed that 125 new Covid-19 positive cases have been reported, with 95 cases linked to the tabligh gathering at Kuala Lumpur’s Jamek Sri Petaling Mosque, which ran from February 27 to March 1. This brings the total number of positive cases in Malaysia to 553, with 42 having since been declared free of Covid-19 and discharged. ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() Roche launch Perjeta - Herceptin combination, a post surgery treatment for early breast cancer (eBC)
![]() ![]() ![]() Keytruda with chemotherapy to be the first line of treatment for patients with advanced lung cancer
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |